Program
duvakitug
Also written as “Duvakitug”, “TEV-48574” and “TEV-48574 Dose Regimen A”.
In Sanofi's pipeline, TL1A mAb
. Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Hidradenitis · Asthma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 66 open or running | phase 3since Sep 15, 2025 | Sep 15, 2025 | May 9, 2028phase 3 · NCT07184996 |
| Teva Pharmaceutical Industries | 31 open or running | phase 2since Aug 24, 2020 | Aug 24, 2020 | none ahead |
- Named in Sanofi’s own pipeline as
duvakitug
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 24, 2020First study: phase 2 study in AsthmaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT04545385 · 65 enrolled · United States, Bulgaria, Czechia and more
- Aug 11, 2022Phase 2 study in Crohn DiseaseTeva Pharmaceutical Industries · NCT05499130 · 290 enrolled · United States, Austria, Belgium and more
- Dec 12, 2022Phase 2 study in Crohn DiseaseTeva Pharmaceutical Industries · NCT05668013 · 247 enrolled · United States, Austria, Bulgaria and more
- Sep 15, 2025Sanofi's first studies: 4 phase 3 studiesNew to SanofiSanofi · NCT07185009, NCT07184996, NCT07184944 and 1 more
- Sep 4, 2026Phase 2 study in HidradenitisSanofi · NCT07812116 · 156 planned · United States, Canada
- Nov 2, 2026Phase 1 study in Colitis, UlcerativeSanofi · NCT07923383 · 25 planned
Ahead
- May 9, 2028Primary completion: phase 3 study in Colitis, UlcerativeSanofi · NCT07184996
- Jun 16, 2028Primary completion: phase 2 study in HidradenitisSanofi · NCT07812116
- Aug 8, 2028Primary completion: phase 1 study in Colitis, UlcerativeSanofi · NCT07923383
- Sep 21, 2028Primary completion: phase 3 study in Colitis, UlcerativeSanofi · NCT07185009
TargetBeta
“TL1A mAb”the company's pipeline, read by Claude · source
Other programs on TNFSF15
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| PF-07261271 | Pfizer | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07923383Colitis, Ulcerative | 1 | Not yet recruiting | Sanofi | Aug 8, 2028 | 25 |
| NCT07812116Hidradenitis · United States, Canada | 2 | Recruiting | Sanofi | Jun 16, 2028 | 156 |
| NCT07185009Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Recruiting | Sanofi | Sep 21, 2028 | 751 |
| NCT07184996Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Recruiting | Sanofi | May 9, 2028 | 980 |
| NCT07184944Crohn Disease · United States, Australia, Austria and more | 3 | Recruiting | Sanofi | Aug 13, 2029 | 751 |
| NCT07184931Crohn Disease · United States, Argentina, Australia and more | 3 | Recruiting | Sanofi | May 14, 2029 | 980 |
| NCT05668013Crohn Disease · United States, Austria, Bulgaria and more | 2 | Active, not recruiting | Teva Pharmaceutical Industries | Jan 5, 2026 | 247 |
| NCT05499130Crohn Disease · United States, Austria, Belgium and more | 2 | Completed | Teva Pharmaceutical Industries | Nov 12, 2024 | 290 |
| NCT04545385Asthma · United States, Bulgaria, Czechia and more | 2 | Terminated | Teva Pharmaceutical Industries | Jan 17, 2022 | 65 |
How it is read
Names in the registry
- “Duvakitug”, 6 entries
- “TEV-48574”, 2 entries
- “TEV-48574 Dose Regimen A”, 1 entry
- “TEV-48574 Dose Regiment B”, 1 entry
Conditions, from the studies’ own filings
- Crohn Disease, 4 studies
- Colitis, Ulcerative, 3 studies
- Hidradenitis, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.